Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its
stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-α) results …

Conventional anticancer therapy using cytotoxic drugs lacks selectivity and is prone to
toxicity and drug resistance. Anticancer therapies targeting aberrant growth factor receptor …

Gene amplification, over-expression, and mutation of growth factors, or the receptors
themselves, causes increased signaling through receptor kinases, which has been …

Squamous cell head and neck cancer (SCCHN) is the seventh most common cause of
cancer death worldwide and its incidence is rising rapidly in developing countries. Despite …

Dermatologic events are considered the most relevant elements of the toxicity profile of
epidermal growth factor receptor (EGFR) inhibitors. However, some nondermatologic …

Cetuximab (Erbitux), a chimeric antiepidermal growth factor receptor monoclonal antibody
currently used to treat metastatic colorectal cancer, is in clinical development for several …

Opinion statement Extensive treatment-related morbidities and stagnant survival rates over
the past few decades for patients with squamous cell cancer of the head and neck (SCCHN) …

As inhibitors of the epidermal growth factor receptor (EGFR) become an increasingly
common therapeutic option in cancer, appropriate management of their associated toxicities …

Targeted biologic therapy for cancer has evolved from the laboratory to active clinical
protocols and applied clinical practice in selected patients. Major targets include epidermal …

Tailored therapy aims to cure a patient who suffers from a specific disease with an effective
and safe drug, based on the complex interactions among patient's characteristics, disease …